US STOCKS-Wall Street slips as stimulus deadlock weighs


Warning: This material has been prepared by a third party company, Reuters, which is independent of Davy. Davy has not reviewed the material and accepts no responsibility for errors or omissions, or for the information or opinions contained therein. It does not constitute investment advice.

 (For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window.)
    * Gilead up as remdesivir wins approval for treating COVID
in U.S.
    * Intel slumps as quarterly margins fall
    * American Express drops as profit falls short of estimates
    * Indexes dip: Dow 0.53%, S&P 0.18%, Nasdaq 0.30%

 (Updates to early afternoon)
    By Medha Singh and Shivani Kumaresan
    Oct 23 (Reuters) - Wall Street's main indexes fell in Friday
afternoon trading as investors fretted over an impasse in
Washington on the new coronavirus aid bill, while turning
cautious ahead of the Nov. 3 presidential election.
    The biggest weight on the three indexes was a 10.5% slump in
chipmaker Intel Corp  INTC.O  after it reported a drop in
margins as consumers bought cheaper laptops and
pandemic-stricken businesses and governments clamped down on
data center spending.*:nL4N2HD4IR
    Uncertainty over the timeline of the relief legislature has
been weighing on Wall Street's major indexes, which were set to
cap a choppy week lower.
    U.S. House Speaker Nancy Pelosi said it still was possible
to get another round of COVID-19 aid before the election, but
that it was up to President Donald Trump to act, including
talking to reluctant Senate Republicans, if he wants it.*:nL1N2HE0ZN
    Treasury Secretary Steven Mnuchin on the other hand said a
deal was possible if Pelosi was willing to compromise.*:nW1N2G500I
    "We are kind of on a hold at this point ... still waiting
for something to come out of Washington," said Paul Nolte,
portfolio manager at Kingsview Asset Management in Chicago.
    "Our base case is that we don't get a meaningful stimulus
package until after the election and probably not until first
    Meanwhile, a record 50 million Americans cast ballots,
eclipsing total early voting from the 2016 election. President
Donald Trump and Democratic rival Joe Biden debated on Thursday
for the last time to persuade the few remaining undecided voters
11 days before their contest.*:nL8N2HE4UL*:nL1N2HD0U2
    Heading into the debate, Trump trailed former vice president
Biden in national polls, but the contest is much tighter in some
battleground states where the election will likely be decided.
    At 12:41 p.m. ET, the Dow Jones Industrial Average  .DJI 
was down 148.98 points, or 0.53%, at 28,214.68, the S&P 500
 .SPX  was down 6.23 points, or 0.18%, at 3,447.26. The Nasdaq
Composite  .IXIC  was down 34.27 points, or 0.30%, at 11,471.74.
    The energy index  .SPNY  dropped 1%, the most among 11 major
S&P sectors.
    The third-quarter earnings season chugged along, with about
84% of the 135 S&P 500 companies that have reported so far
topping quarterly profit estimates, according to Refinitiv data.
    Next week's focus will be on results from Big Tech companies
Apple Inc  AAPL.O , Facebook Inc  FB.O , Inc  AMZN.O 
and Google-parent Alphabet  GOOGL.O .
    Gilead Sciences Inc  GILD.O  rose 0.9% as its antiviral drug
remdesivir became the first and only drug approved for treating
patients hospitalized with COVID-19 in the United States.*:nL4N2HD4I1
    American Express Co  AXP.N  dropped 3.7% as it missed
estimates for third-quarter profit after its customers spent
less during the COVID-19 fueled economic slowdown and it set
aside money for potential payment defaults.*:nL4N2HE33Q
    Advancing issues outnumbered decliners by a 1.08-to-1 ratio
on the NYSE. Declining issues outnumbered advancers for a
1.07-to-1 ratio on the Nasdaq.
    The S&P index recorded 25 new 52-week highs and no new low,
while the Nasdaq recorded 50 new highs and 12 new lows.

 (Reporting by Medha Singh and Shivani Kumaresan in Bengaluru;
Editing by Anil D'Silva and Maju Samuel)
 ((; within U.S. +1646 223 8780,
outside U.S. +91 80 6182 2802; Twitter:;))

Warning: This content may be provided by regulated and unregulated entities and is not created, reviewed or endorsed by Davy. It is provided for general information purposes only and does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. Importantly, it does not constitute investment advice, as it does not contemplate the personal circumstances of any particular person or group of persons. Neither Davy nor the providers of the Third Party Content will be liable for any investment decision made based on the reliance on or use of such data, or any liability that may arise due to delays or interruptions in the delivery of the Third Party Content for any reason.